Horm Metab Res 2012; 44(03): 157-162
DOI: 10.1055/s-0031-1295438
© Georg Thieme Verlag KG Stuttgart · New York

Prevalence of Primary Aldosteronism in Patient’s Cohorts and in Population-based Studies – A Review of the Current Literature

A. Hannemann
1   Institute of Clinical Chemistry and Laboratory Medicine, Ernst-Moritz-Arndt-University Greifswald, Germany
H. Wallaschofski
1   Institute of Clinical Chemistry and Laboratory Medicine, Ernst-Moritz-Arndt-University Greifswald, Germany
› Author Affiliations
Further Information

Publication History

received 25 August 2011

accepted 26 October 2011

Publication Date:
01 December 2011 (online)


There is an ongoing controversy on the prevalence of primary aldosteronism (PA). We aimed to update a meta-analysis published in 2008, that compiled studies reporting the prevalence of positive ARR screening tests and PA. We therefore reviewed original studies published in 2008 or later to examine whether current reports provide similar, higher or lower prevalences of elevated ARRs or PA than reports included in the original meta-analysis. A systematic review of English articles using PubMed was conducted. Search and extraction of articles were performed by one review author; the second review author checked all extracted data. We identified 11 eligible studies. The updated, weighted mean prevalences of elevated ARRs and PA in primary care (prevalence of high ARRs 16.5%; prevalence of PA 4.3%) and referred patients (prevalence of high ARRs 19.6%; prevalence of PA 9.5%) were only marginally different from the mean values obtained in the original meta-analysis. Among the current studies the maximum values for the prevalence of elevated ARRs and PA were substantially lower than among the older studies. Our results confirm the main conclusions from the original meta-analysis. The prevalence of PA increases with the severity of hypertension and the inclusion of current study results did not alter the mean prevalences of elevated ARRs and PA in primary care and referred patients. Additionally, we found that current studies focus increasingly on patients in referral centers or special subgroups, while the prevalence of PA in the general hypertensive population is yet unknown.

  • References

  • 1 Funder JW, Reincke M. Aldosterone: a cardiovascular risk factor?. Biochim Biophys Acta 2010; 1802: 1188-1192
  • 2 Gomez-Sanchez CE, Rossi GP, Fallo F, Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res 2010; 42: 374-381
  • 3 Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66: 607-618
  • 4 Mantero F, Mattarello MJ, Albiger NM. Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes 2007; 115: 171-174
  • 5 Quack I, Vonend O, Rump LC. Familial hyperaldosteronism I–III. Horm Metab Res 2010; 42: 424-428
  • 6 Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008; 29: 133-154
  • 7 Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14: 235-241
  • 8 Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
  • 9 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
  • 10 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
  • 11 Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 2010; 42: 435-439
  • 12 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
  • 13 Catena C, Colussi G, Di Fabio A, Valeri M, Marzano L, Uzzau A, Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010; 42: 440-445
  • 14 Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
  • 15 Tomaschitz A, Pilz S. Aldosterone to renin ratio – a reliable screening tool for primary aldosteronism?. Horm Metab Res 2010; 42: 382-391
  • 16 Gordon RD. Primary aldosteronism – actual epidemics or false alarm?. Arq Bras Endocrinol Metabol 2004; 48: 666-673
  • 17 Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 2006; 154: 865-873
  • 18 Mulatero P, Monticone S, Bertello C, Mengozzi G, Tizzani D, Iannaccone A, Veglio F. Confirmatory tests in the diagnosis of primary aldosteronism. Horm Metab Res 2010; 42: 406-410
  • 19 Westerdahl C, Bergenfelz A, Isaksson A, Wihl A, Nerbrand C, Valdemarsson S. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scand J Prim Health Care 2006; 24: 154-159
  • 20 Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89: 4221-4226
  • 21 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
  • 22 Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003; 17: 591-605
  • 23 Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318
  • 24 Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-394
  • 25 Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859
  • 26 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young Jr WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050
  • 27 Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
  • 28 Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-315
  • 29 Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165
  • 30 Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007; 30: 111-117
  • 31 Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705
  • 32 Boscaro M, Ronconi V, Turchi F, Giacchetti G. Diagnosis and management of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 2008; 15: 332-338
  • 33 Jansen PM, Boomsma F, van den Meiracker AH. Aldosterone-to-renin ratio as a screening test for primary aldosteronism – the Dutch ARRAT Study. Neth J Med 2008; 66: 220-228
  • 34 Mulatero P, Monticone S, Bertello C, Tizzani D, Iannaccone A, Crudo V, Veglio F. Evaluation of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 2010; 17: 188-193
  • 35 Rossi GP. Prevalence and diagnosis of primary aldosteronism. Curr Hypertens Rep 2010; 12: 342-348
  • 36 Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 2007; 50: 447-453
  • 37 Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 2007; 50: 454-458
  • 38 Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102
  • 39 Westerdahl C, Bergenfelz A, Isaksson A, Nerbrand C, Valdemarsson S. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scand J Prim Health Care 2011; 29: 57-62
  • 40 Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, Saponara M, Letizia C. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-172
  • 41 Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926
  • 42 Mysliwiec J, Zukowski L, Grodzka A, Pilaszewicz A, Dragowski S, Piekut B, Nikolajuk A, Gorska M. Problems in diagnostics of primary aldosteronism – analysis of the own data. Endokrynol Pol 2010; 61: 2-5
  • 43 Nogueira AR, Bloch KV. Screening for primary aldosteronism in a cohort of Brazilian patients with resistant hypertension. J Clin Hypertens (Greenwich) 2008; 10: 619-623
  • 44 Ribeiro MJ, Figueiredo Neto JA, Memoria EV, Lopes Mde C, Faria Mdos S, Salgado Filho N, Oliveira TC. Prevalence of primary hyperaldosteronism in a systemic arterial hypertension league. Arq Bras Cardiol 2009; 92: 39-45
  • 45 Borgel J, Springer S, Ghafoor J, Arndt D, Duchna HW, Barthel A, Werner S, Van Helden J, Hanefeld C, Neubauer H, Bulut D, Mugge A. Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence. Clin Res Cardiol 2010; 99: 499-506
  • 46 Hiroi N, Sue M, Yoshihara A, Ichijo T, Yoshida-Hiroi M, Higa M, Yoshino G. Prevalence of adrenal masses in Japanese patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2010; 2: 71
  • 47 Tapolyai M, Uysal A, Dossabhoy NR, Zsom L, Szarvas T, Lengvarszky Z, Fulop T. High prevalence of liddle syndrome phenotype among hypertensive US Veterans in Northwest Louisiana. J Clin Hypertens (Greenwich) 2010; 12: 856-860
  • 48 Mukherjee JJ, Khoo CM, Thai AC, Chionh SB, Pin L, Lee KO. Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism. Diab Vasc Dis Res 2010; 7: 6-13
  • 49 Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism – part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol 2008; 21: 447-454
  • 50 Young Jr WF. Minireview: primary aldosteronism – changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-2213
  • 51 Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005; 90: 72-78
  • 52 Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest. J Appl Physiol 2004; 96: 1406-1414
  • 53 Koch M, Aker S, Haastert B, Rump LC. Clinical relevance of dietary salt intake on aldosterone and the aldosterone-to-renin ratio as screening parameters for primary aldosteronism. Clin Nephrol 74: 182-189
  • 54 Fommei E, Ghione S, Ripoli A, Maffei S, Di Cecco P, Iervasi A, Turchi S. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women. J Hum Hypertens 2009; 23: 130-135
  • 55 Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?. J Clin Endocrinol Metab 2011; 96: E340-E346
  • 56 Kotliar C, Inserra F, Forcada P, Cavanagh E, Obregon S, Navari C, Castellaro C, Sanchez R. Are plasma renin activity and aldosterone levels useful as a screening test to differentiate between unilateral and bilateral renal artery stenosis in hypertensive patients?. J Hypertens 2010; 28: 594-601
  • 57 Stowasser M, Gordon RD, Klemm SA, Tunny TJ. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis. J Clin Endocrinol Metab 1993; 77: 800-804
  • 58 Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457-465
  • 59 Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. Hypertension 2002; 40: 897-902
  • 60 Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329-337
  • 61 Dorrian CA, Toole BJ, Alvarez-Madrazo S, Kelly A, Connell JM, Wallace AM. A screening procedure for primary aldosteronism based on the Diasorin Liaison automated chemiluminescent immunoassay for direct renin. Ann Clin Biochem 2010; 47: 195-199
  • 62 Hannemann A, Friedrich N, Ludemann J, Volzke H, Rettig R, Peters J, Reincke M, Doring A, Nauck M, Wallaschofski H. Reference intervals for aldosterone, renin, and the aldosterone-to-renin ratio in the population-based Study of Health in Pomerania (SHIP-1). Horm Metab Res 2010; 42: 392-399
  • 63 Niizuma S, Nakahama H, Kamide K, Fukuchi K, Iwanaga Y, Nakata H, Yoshihara F, Horio T, Nakamura S, Kawano Y. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine. Clin Exp Hypertens 2008; 30: 640-647
  • 64 Rossi GP, Barisa M, Belfiore A, Desideri G, Ferri C, Letizia C, Maccario M, Morganti A, Palumbo G, Patalano A, Roman E, Seccia TM, Pessina AC, Mantero F. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010; 28: 1892-1899
  • 65 Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. Clin Biochem Rev 2010; 31: 39-56
  • 66 Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006; 52: 1749-1755
  • 67 Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem 2009; 55: 1155-1162
  • 68 Ahmed AH, Calvird M, Gordon RD, Taylor PJ, Ward G, Pimenta E, Young R, Stowasser M. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab 2011; 96: 1039-1045
  • 69 Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96: 1797-1804
  • 70 Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12: 43-48
  • 71 Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16: 86-91
  • 72 Funder JW. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007; 50: 840-841
  • 73 Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens 2008; 26: 613-621